Dasatinib (BMS-354825) is an oral dual BCR/ABL and SFK inhibitor approved for use in patients with CML and Philadelphia chromosome-positive acute lymphoblastic leukemia [41-44]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.